Vol. 5 No. 10 (2025)
Reimbursement Recommendations

Belantamab Mafodotin, Pomalidomide, Dexamethasone

decorative image of the issue cover

Published October 28, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Blenrep in combination with pomalidomide and dexamethasone be reimbursed by public drug plans for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including lenalidomide, if certain conditions are met.
  • Blenrep in combination with pomalidomide and dexamethasone should only be covered to treat adults with relapsed or refractory multiple myeloma who are in relatively good health and have already tried at least 1 other lenalidomide-containing regimen for this disease. Blenrep in combination with pomalidomide and dexamethasone should not be reimbursed in patients who were previously treated with an anti-BCMA therapy or pomalidomide.
  • Blenrep in combination with pomalidomide and dexamethasone should only be reimbursed if it is prescribed under the care of a clinician with expertise in the diagnosis and management of patients with multiple myeloma, and the cost of Blenrep is reduced.